“Rising Demand for Minimally Invasive Neuromodulation Therapies”
- A growing trend in the Europe vagus nerve stimulation (VNS) market is the increasing demand for minimally invasive neuromodulation techniques to treat neurological and psychiatric disorders, such as epilepsy, depression, and cluster headaches. VNS therapy offers long-term relief with fewer side effects compared to pharmaceutical options, making it increasingly attractive for both patients and healthcare providers
- For instance, LivaNova PLC, a key player in the VNS space, has expanded its portfolio with advanced implantable pulse generators that offer improved programmability and longer battery life, enhancing patient comfort and treatment outcomes
- Europe is witnessing a rising prevalence of neurological conditions, with epilepsy alone affecting more than 6 million people in the region. This has resulted in greater adoption of alternative therapies like VNS, especially where traditional treatments fail or lead to adverse effects. Moreover, increasing awareness among healthcare professionals and patients regarding the benefits of VNS therapy is expected to further drive market expansion
- Technological advancements, including smaller implant sizes, improved battery longevity, and MRI-compatible devices, are improving the safety and efficacy profile of VNS systems. These improvements are boosting the adoption rate of the therapy across European countries such as Germany, France, and the U.K.
- Furthermore, the European market benefits from supportive regulatory frameworks and growing investment in neurological research. Reimbursement policies in countries like Germany and the Netherlands also promote the uptake of VNS devices, particularly for treatment-resistant depression and refractory epilepsy
- With the continued evolution of personalized medicine and increased clinical trial data supporting VNS efficacy, the market is set to experience robust growth in the coming years. Companies like ElectroCore and Nevro are actively exploring non-invasive VNS options, expanding accessibility and opening new patient segments
